H.C. Wainwright reiterates Brainsway stock rating on strategic collaboration

H.C. Wainwright reiterated a Buy rating and $19.00 price target for Brainsway (BWAY), citing a 71% upside potential. The company announced a strategic collaboration with Mindful Health Solutions to expand access to mental health treatments. Brainsway reported Q2 2026 revenue of $17.1 million, exceeding estimates, and raised its full-year revenue outlook to $68-$70 million. The stock has shown 32% revenue growth and a 75% gross profit margin over the last year.

Original reporting
Published Nov 3, 2026, 12:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$BWAY
Bullish
high confidence
Mentioned
$BWAY
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BWAYBullishMed
01

Why it matters

The strategic partnership expands clinic footprint and insurance coverage, supporting a higher revenue outlook and a new analyst price target.

02

Market read

The news provides a fresh catalyst for BWAY, potentially driving short‑term price appreciation.

03

What to watch

Potential regulatory scrutiny of at‑home neuromodulation therapy and competition from other TMS providers could temper growth.

Relevance 6/10Novelty 6/10Timing: today

Background

Brainsway (NASDAQ:BWAY) is a small‑cap medical‑device company focused on deep transcranial magnetic stimulation for depression and OCD.

Company-level read

Ticker impact

$BWAYBullishHigh confidence
Context

Brainsway announced a strategic collaboration with Mindful Health Solutions, expanding access to its Deep TMS treatments and prompting an analyst price target raise.

Expected impact

likely upward pressure as investors price in expanded market reach and higher revenue outlook

Evidence & confidence

The partnership adds new clinic locations and insurance coverage, supporting the analyst's $19 target and a 71% upside.

Market effects

May lift other neurostimulation and mental‑health device makers as the market sees increased acceptance of non‑invasive treatments.

Strengthens the U.S. behavioral‑health technology segment, especially in the listed states where new clinics open.

Limited to niche medical‑device space; broader market impact modest.

Counterpoint

The collaboration may not translate into immediate sales if reimbursement hurdles persist, keeping upside limited.

Key entities

  • Brainsway

    Developer of Deep TMS neurostimulation systems.

  • Mindful Health Solutions

    Provider of behavioral health services now under Radial Health.

Related articles

$BWAYMed

Brainsway Ltd. (BWAY): Financial results for Q3 2026

Brainsway Ltd. (BWAY) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 BrainsWay Reports Third Quarter 2026 Financial Results and Operational Highlights Revenue increased 3 4 % to $18. 1 million in Q3 2026 ; Operating income rose 107 % to $2. 6 million and Adjusted EBITDA rose approximately 92 % to $ 3 . 9 million Remaining performance

$BWAYMedAI 8/10

BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™

BrainsWay Ltd. (NASDAQ: BWAY) reported results from a pilot study on its Deep TMS™ technology in patients with depression and early-stage Alzheimer’s disease. The study showed an 83.3% response rate and 50% remission rate in depressive symptoms, with measurable changes in brain activity. The study was published in the Journal of Geriatric Psychiatry and Neurology.

$BWAYMedAI 8/10

Brainsway Q2 Earnings Call Highlights

BrainsWay (NASDAQ:BWAY) reported Q2 gross profit up 34% to $12.8M with gross margin at 75%. Management cited a 30% backlog increase and SWIFT reimbursement progress, estimating 57M US covered lives. CFO Ido Marom said operating cash flow was $6.3M and raised 2026 revenue guidance to $68M-$70M. The company is also discussing Neurolief’s ProlivRx soft launch.